Elixxer Stock Price, News & Analysis

Elixxer Ltd. (OTC Pink: ELIXF) is a Canadian public company that describes itself as an investment company with investments in Canada and other countries. According to its public disclosures, Elixxer is listed on the TSX Venture Exchange under the symbol ELXR or ELXR.H and on the US OTC-Pink market under the symbol ELIXF. The company states that it is currently looking for new high growth opportunities to invest in.

Elixxer’s public communications indicate that it focuses on identifying and evaluating potential transactions and merger and acquisition opportunities. The company has disclosed that it is actively pursuing opportunities to merge an operating business into Elixxer in order to grow the company, while noting that no agreements or letters of interest had been entered into at the time of its corporate update.

Business focus and investment activities

In its news releases, Elixxer explains that it operates as an investment company with exposure to businesses in Canada and other countries. One disclosed investment is an equity interest in Freia Farmaceutici Srl ("Freia"), where Elixxer completed cash investment tranches and reported holding a minority equity interest. Elixxer has also reported involvement in litigation related to a convertible debenture with Tricho-Med Corporation, including court applications concerning immovable property pledged as security and related proceedings.

The company’s disclosures describe the use of advisory services and financing arrangements to support its activities. For example, Elixxer has referred to M&A advisory services provided under an agreement with AIP Asset Management Inc., and has outlined the role of AIP Convertible Private Debt Fund L.P. as a significant creditor and shareholder. These arrangements have been discussed in the context of debt settlements and bridge financing.

Capital structure, debt and related party transactions

Elixxer has issued several news releases describing its debt obligations and steps taken to manage them. The company has discussed secured promissory notes held by AIP Convertible Private Debt Fund L.P., amendments extending the maturity of these notes, and an unsecured promissory grid note used as a bridge loan. It has also described a series of proposed and completed shares-for-debt settlements, where indebtedness to arm’s length and non-arm’s length creditors was to be or has been settled through the issuance of common shares at a specified price per share.

These transactions have been characterized as related party transactions under Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions ("MI 61-101"), because insiders or control persons of the company received or were expected to receive common shares. Elixxer has explained in its disclosures which exemptions from valuation and minority shareholder approval requirements under MI 61-101 it relied on or proposed to rely on, and when disinterested shareholder approval was required under TSX Venture Exchange policies.

Corporate governance and shareholder approvals

Elixxer has reported on several annual and special meetings of shareholders, where shareholders voted on matters such as:

• Election of directors for the ensuing year.
• Appointment of auditors and approval of changes in audit firms.
• Amendments to the company’s articles, including changing the province of its registered office.
• Approval and confirmation of stock option plans, including a conversion from a fixed plan to a rolling plan and the adoption of a rolling 10% stock option plan.
• Approval of debt settlements through the issuance of common shares to creditors.
• Approval of a proposed name change, to be determined by the board of directors.
• Approval of a consolidation of common shares on a basis approved by shareholders.
• Approval of a voluntary delisting of the company’s common shares from the TSX Venture Exchange and a plan to list on another recognized stock exchange, subject to the applicable shareholder approvals and regulatory processes.

The company’s news releases provide voting results for these resolutions and identify when matters were approved by disinterested shareholders or by a majority of the minority, in accordance with securities regulations and exchange policies.

Trading status and regulatory history

Elixxer has disclosed that its shares were subject to Failure-to-File Cease Trade Orders issued by the Autorité des Marchés Financiers and the Ontario Securities Commission after the company did not file various continuous disclosure documents. The company later announced that these cease trade orders were revoked after its continuous disclosure filings, including audited financial statements and management’s discussion and analysis, were brought up to date and made available on SEDAR+.

In a subsequent corporate update, Elixxer indicated that it expected its shares to be reinstated for trading after the revocation of the cease trade orders. Later disclosures describe the company’s listing status on the TSX Venture Exchange under symbols ELXR and ELXR.H and its intention, subject to shareholder approval, to voluntarily delist from the TSX Venture Exchange and seek listing on another recognized stock exchange.

Financing arrangements and bridge loan

Elixxer has reported entering into an unsecured promissory grid note with a non-arm’s length lender, described as a control person of the company, for available proceeds up to a specified amount. The company has explained that this bridge loan was intended to reimburse a prior unsecured bridge loan and to fund general and administrative expenses and capital requirements. The terms disclosed include a maturity date, interest rates, and the requirement for corporate and regulatory approvals, including acceptance by the TSX Venture Exchange.

The company has also described amendments to existing secured promissory notes, including extensions of maturity dates and the accumulation of accrued interest. These arrangements form part of Elixxer’s disclosed efforts to manage its outstanding loans and financial obligations.

Legal proceedings and investments

Elixxer has provided updates on its litigation with Tricho-Med Corporation, relating to a convertible debenture and security over immovable property. The company has reported filing an application with the Superior Court of Quebec for surrender and taking in payment of the property, and has described subsequent developments, including a judicial sale process initiated by a subcontractor holding a legal hypothec. Elixxer has indicated that, upon sale of the property, its hypothec would convert into a personal monetary claim and that it retains certain rights in relation to the sale.

In addition, Elixxer has described its investment in Freia Farmaceutici Srl, including the execution of a definitive investment agreement, completion of investment tranches, the resulting equity interest, and the impact of additional financing raised by Freia on Elixxer’s percentage interest. The company has noted that it appointed a representative to Freia’s board of directors.

Regulatory framework and disclosures

Across its public communications, Elixxer references compliance with TSX Venture Exchange policies, including Policy 4.4 on security-based compensation and policies governing related party transactions and debt settlements. It also refers to MI 61-101 in connection with related party transactions, valuation requirements, and minority shareholder approval. The company’s news releases include cautionary language regarding forward-looking information and direct readers to its management’s discussion and analysis on SEDAR+ for a description of risks and uncertainties facing the company.

Frequently Asked Questions about Elixxer Ltd. (ELIXF)